Show simple item record

dc.contributor.authorKrishnan, B
dc.contributor.authorMatutes, E
dc.contributor.authorDearden, C
dc.date.accessioned2018-09-04T11:58:58Z
dc.date.issued2006
dc.identifier2
dc.identifier.citationSeminars in Oncology, 2006, 33 pp. 257 - 263
dc.identifier.issn0093-7754
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2548
dc.identifier.doi10.1053/j.seminoncol.2006.01.015
dc.description.abstractT and B subtypes of prolymphocytic leukemias (PLLs) are rare, highly aggressive lymphoid malignancies with characteristic morphologic, immunophenotypical, cytogenetic, and molecular features. Recent studies have highlighted the role of specific oncogenes such as TCL1, MTCP-1, and ATM in the case of T-cell and p53 mutations in the case of B-cell PLLs. Despite the advances in the understanding of the biology of these conditions, prognosis for these patients remains poor with short survival and no curative treatment. The advent of monoclonal antibody therapy has improved treatment options for this group. In particular, the use of Campath-1H, in T-PLL has more than doubled median survival. The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored further.
dc.format.extent257 - 263
dc.languageeng
dc.language.isoeng
dc.titleProlymphocytic Leukemias
dc.typeJournal Article
rioxxterms.versionofrecord10.1053/j.seminoncol.2006.01.015
rioxxterms.licenseref.startdate2006
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfSeminars in Oncology
pubs.notesChronic Lymphocytic Leukemia
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume33
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMatutes, Estellaen
dc.contributor.icrauthorDearden, Claireen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record